Kirkland Represents Celator Pharmaceuticals in $1.5 Billion Acquisition by Jazz Pharmaceuticals

Kirkland & Ellis LLP represents Celator Pharmaceuticals (Nasdaq: CPXX), which announced today it has entered into a definitive agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) pursuant to which Jazz Pharmaceuticals will acquire Celator in a transaction valued at approximately $1.5 billion.

The transaction is structured as a tender offer and second step merger. The closing of the tender offer is subject to customary conditions, including the tender of a majority of the outstanding Celator shares and expiration or termination of the Hart Scott Rodino waiting period. The transaction is expected to close in the third quarter of 2016. More information on the transaction is available here.

The Kirkland team includes corporate partners Daniel Wolf and David Feirstein and associates Clement Smadja and Jennifer Basch. Other advisors on the transaction include: MTS Health Partners as financial advisor for Celator; RBC Capital Markets as financial advisor and Cooley LLP as legal advisor to Jazz Pharmaceuticals.